A dose of clarity for pharma investors

Geopolitical conflict and policy issues have created uncertainty for companies, investors and markets this year. However, the European Union and the White House have provided some clarity, revealing that tariffs on US pharmaceutical imports will be capped at 15%. Tariffs on car manufacturers will fall to the same rate, once the EU removes its fees on agricultural and seafood products. Last month’s initial agreement was criticised over a lack of detail, impacting drug stocks. But experts believe that these developments are good news for Europe, avoiding President Trump’s 200% tariff threats and...